Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Apply
Pembrolizumab, Lenvatinib, N-803
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step